Morphine (Chlorhydrate) Lavoisier (Morphine Hydrochloride)

Morphine, the active ingredient in Morphine (Chlorhydrate) Lavoisier, is an opioid analgesic presented as a sterile injectable solution for epidural, intrathecal, and intravenous use. It is employed to manage severe acute, postoperative and cancer‑related pain in adult patients. GNH USA supplies Morphine (Chlorhydrate) Lavoisier as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Morphine is an opioid analgesic that acts on the central nervous system to relieve intense pain. It is indicated for: - Severe acute pain: provides rapid relief after trauma or surgery. - Post‑operative pain: controls pain following major operative procedures. - Cancer‑related pain: manages moderate to severe pain associated with malignant disease. - Chronic severe pain: used when other analgesics are insufficient, under strict medical supervision.

Morphine may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea: feeling of sickness often accompanied by vomiting. - Constipation: reduced bowel motility leading to hard stools. - Drowsiness: increased sedation and reduced alertness. - Itching: pruritus, especially around the face and neck. - Sweating: excessive perspiration unrelated to temperature. - Dry mouth: reduced salivation causing discomfort.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be fatal. - Severe hypotension: marked drop in blood pressure causing dizziness. - Adrenal insufficiency: impaired cortisol production. - Dependence and withdrawal: physical reliance with withdrawal symptoms on abrupt cessation. - Anaphylaxis: rare severe allergic reaction with rash, swelling, and airway compromise. - Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

Morphine requires careful monitoring due to its potency and risk profile. - Respiratory monitoring: assess breathing rate and depth regularly, especially after dose changes. - Cardiovascular assessment: watch for hypotension and treat promptly if symptomatic. - Renal/hepatic impairment: adjust dosing in patients with reduced organ function. - Allergy screening: avoid use in individuals with known hypersensitivity to morphine or other opioids. - Pregnancy and lactation: risk unknown; reserve for situations where benefit outweighs potential harm. - Store below 25°C: keep in original container, protect from light and moisture.

Morphine can interact with several drug classes, altering its efficacy or safety.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound sedation or respiratory depression. - MAO inhibitors: can precipitate severe hypertension or serotonin syndrome. - Respiratory depressants (e.g., anesthetic gases): increase risk of fatal respiratory failure.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise morphine plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect. - Diuretics: can enhance hypotensive effects. - Antihistamines: may increase sedation and dizziness.